Treatment of severe acute graft-versus-host disease refractory to multiple lines of therapy: Real-world data from 317 adults treated with the multiple-donor bone marrow-derived mesenchymal stromal cell preparation tomostrocel.

Date publication

septembre 2026

Journal

Transplantation and cellular therapy

Auteurs

Membres identifiés du Cancéropôle Est :
Dr D'AVENI-PINEY Maud

Tous les auteurs :
Verbeek M, Bonig H, Ayuk F, Bug G, D'Aveni-Piney M, Heidenreich D, Herhaus P, Holtick U, Kos I, Krüger W, Lupo-Stanghellini MT, Mika T, Neuerburg C, Osswald E, Panagiota V, Reicherts C, Schmid C, Srour M, Stölzel F, Tribanek M, Wortmann F, Wulf G, Zens A, Zeiser R

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/42731730

Résumé

Patients with severe, multi-refractory acute graft-versus-host disease (aGvHD) after hematopoietic stem cell transplantation (HSCT) have a dismal prognosis, but mesenchymal stromal cells (MSC) have emerged as a promising treatment option. A unique bone marrow-derived off-the-shelf MSC product generated from multiple donors, i.e. human allogeneic mesenchymal stromal cells DRK-BaWü-He-FFM (tomostrocel, formerly referred to as MSC-FFM), is currently under development. Tomostrocel is also distributed under Hospital Exemption in Germany and Named Patient Use elsewhere in Europe, with data of treated patients captured in a dedicated surveillance program.

Mots clés

MSC-FFM, Tomostrocel, acute graft-versus-host disease, allogeneic hematopoietic stem cell transplantation, cell therapy, mesenchymal stromal cells, steroid-refractory

Référence

Transplant Cell Ther. 2026 09 12;: